Jennifer E. Altomonte Geburtsdatum

Persönliche Daten
Jennifer E. Altomonte
22.01.1976
Name:
Geburtsdatum:
Wissenschaftlicher Werdegang
1994 - 1999
1999 - 2006
2003 - 2005
Seit 2006
Bachelor of Science, Pennsylvania State University, University Park, PA;
Hauptfach: Mikrobiologie, Nebenfächer: Biochemie, Molekularbiologie
Technische Assistentin, Labor Prof. Savio Woo, Institute for Gene and Cell Medicine,
Mount Sinai School of Medicine, New York, NY, USA
Master of Science in forensischer Wissenschaft; John Jay College of Criminal Justice,
New York, NY (Masterarbeit: 2009, Helmholtz Zentrum München; Betreuer: Dr. Arne
Pfeufer)
Wissenschaftliche Mitarbeiterin, Labor Dr. med. Oliver Ebert;
2. Medizinische Klinik, Klinikum rechts der Isar der Technischen Universität München,
München
Qualifikationen
•
•
•
•
Molekularbiologische Techniken: Klonierung, zielgerichtete Mutagenese, Northern Blot, PCR,
RT-PCR, qRT-PCR, DNA- und RNA-Präparation, Virusaufreinigung, Reportergen Assays
Proteinbiochemie: SDS-PAGE, Western Blot, ELISA, RIA, ChIP, Immunpräzipitation
Zellkultur: Kultivierung von primären und immortalisierten Zelllinien, Transfektion,
Virusinfektion, Virusgenerierung und Vermehrung, Plaque Assay, TCID50, MTT Assay,
Immunfluoreszenz, Lichtmikroskopie
Tierexperimente: Etablierung von implantierten und spontanen Tumormodellen, Mikrochirurgie:
Nähen, Katheterplazierung, Injektion in die Schwanzvene, Blutabnahme, Anästhesie, postoperative Versorgung, Isolierung von primären Hepatozyten, Sektion, Histologie,
Immunhistochemie
Publikationen
1.
2.
3.
4.
5.
6.
7.
8.
9.
Dong, H., Altomonte, J., Morral, N., Meseck, M., Thung, S.N. and Woo, S.L.C. (2002). Basal
Insulin Gene Expression Significantly Improves Conventional Insulin Therapy in Type 1
Diabetes. Diabetes. 51, 130-139.
Morral, N., McEvoy, R., Dong, H., Meseck, M., Altomonte, J., Thung, S., and Woo, S.L.C.
(2002). Adenovirus-Mediated Expression of Glucokinase in the Liver as an Adjuvant Treatment
for Type 1 Diabetes. Human Gene Therapy. 13, 1561-1570.
Hofmann, S., Dong, H., Li, Z., Cai, W., Altomonte, J., Thung, S.N., Zeng, F., Fisher, E.D., and
Vlassara, H. (2002). Improved Insulin Sensitivity is Associated With Restricted Intake of Dietary
Glycoxidation Products in the db/db Mouse. Diabetes. 51, 2082-2089.
Altomonte, J., Harbaran, S., Richter, A., and Dong, H. (2003). Fat Depot-Specific Expression
of Adiponectin is Impaired in Zucker Fatty Rats. Metabolism. Aug; 2(8):958-63.
Altomonte, J., Richter, A., Harbaran, S., Nakae, J., Meseck, M., Accili, D., and Dong, H.
(2003). Inhibition of Foxo1 Function is Associated with Improved Fasting Glycemia in Diabetic
Mice. American Journal of Physiology, Endocrinology, and Metabolism. 285(4):E718-28
Puigserver, P., Rhee, J., Donovan, J., Yoon, J.C., Walkey, C.J., Oriente, F., Kitamura, Y.,
Altomonte, J., Dong, H., Accili, D., and Spiegelman, B.M. (2003). Insulin-Regulated Hepatic
Gluconeogenesis Through FOXO1-PGC1alpha Interaction. Nature. 423(6939):550-5.
Altomonte, J., Cong, L., Harbaran, S., Richter, A., Xu, J., Meseck, M., and Dong, H. (2004).
Foxo1 mediates insulin action on apoC-III and triglyceride metabolism. J Clin Invest.
114(10):1493-503.
Zhang, N., Richter, A., Suriawinata, J., Harbaran, S., Altomonte, J., Cong, L., Zhang, H., Song,
K., Meseck, M., Bromberg, J., and Dong, H. (2004). Elevated vascular endothelial growth factor
production in islets improves islet graft vascularization. Diabetes. 53(4)963-70.
Dong, H., Maddux, B.A., Altomonte, J., Meseck, M., Accili, D., Terkeltaub, R., Johnson, K.,
Youngren, J.F., and Goldfine, I.D. (2005). Increased hepatic levels of the insulin receptor
inhibitor, PC-1/NPP1, induce insulin resistance and glucose intolerance. Diabetes. 54(2):36772.
10. Qu, S., Altomonte, J., Perdomo, G., He, J., Fan, Y., Kamagate, A., Meseck, M., and Dong, H.
(2006) Aberrant Forkhead box 01 function is associated with impaired hepatic metabolism.
Endocrinology . 147(12):5641-52
11. Qu, S., Su, D., Altomonte, J., Kamagate, A., He, J., Perdomo, G., Tse, T., Jiang, Y., and Dong,
H. (2007) PPARalpha mediates the hypolipidemic action of fibrates by antagonizing FoxO1.
Am J Physiol Endocrinol Metab. 292(2):E421-34
12. Morral. N., Edenberg, H., Witting, SR., Altomonte, J., Chu, T., and Brown, M. (2007). Effects of
glucose metabolism on the regulation of genes of fatty acid synthesis and triglyceride secretion
in the liver. J Lipid Res. 48(7)1499-510.
13. Altomonte, J., Wu, L., Chen, L., Meseck, M., Ebert, O., Garcia-Sastre, A., Fallon, J., and Woo,
SL. (2008). Exponential enhancement of oncolytic Vesicular stomatitis virus potency by vectormediated suppression of inflammatory responses in vivo. Mol Ther. 16(1):146-53
14. Wu, L., Huang, TG, Meseck, M., Altomonte, J., Ebert, O., Shinosaki, K., Garcia-Sastre, A.,
Fallon, J., Mandeli, J., and Woo, SL. (2008). rVSV(MD51)-M3 is an effective and safe oncolytic
virus for cancer therapy. Hum Gene Ther 19(6):635-47.
15. Altomonte, J., Braren, R., Schulz, S., Marozin, M., Rummeny, EJ, Schmid, RM, and Ebert, O.
(2008) Synergystic antitumor effects of transarterial viroembolization for multifocal hepatocellular
carcinoma in rats. Hepatology, 48(6):1864-73.
16. Marozin, S., Altomonte, J., Stadler, F., Thasler, WE, Schmid, RM, and Ebert, O. (2008).
Inhibition of the IFN-b response in hepatocellular carcinoma by alternative spliced isoform of IFN
regulatory factor 3. Mol Ther, 16(11):1789-97.
17. Altomonte, J., Wu, L., Meseck, M., Ebert, O., Garcia-Sastre, A., Fallon, J., and Woo, SL.
(2009) Enhanced oncolytic potency of vesicular stomatitis virus via vector-mediated inhibition of
NK and NKT cells. Cancer Gene Ther, 16(3):266-78.
18. Altomonte, J., Marozin, S., Schmid, RM, and Ebert, O. (2010). Engineered Newcastle Disease
Virus as an improved oncolytic agent against hepatocellular carcinoma. Mol Ther. 18(2):275-84.